{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:38:46Z","timestamp":1784954326484,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.revmed.2025.11.002","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:42:02Z","timestamp":1765975322000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perfusion sous-cutan\u00e9e\u00a0: indications, modalit\u00e9s et tol\u00e9rance"],"prefix":"10.1016","volume":"47","author":[{"given":"Robin","family":"Arcani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Correard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Daumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2025.11.002_bib0305","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-3476(47)80057-5","article-title":"The clinical use of hyaluronidase in hypodermoclysis","volume":"30","author":"Hechter","year":"1947","journal-title":"J Pediatr"},{"key":"10.1016\/j.revmed.2025.11.002_bib0310","first-page":"305","article-title":"The danger of administering parenteral fluids by hypodermoclysis","volume":"32","author":"Abbott","year":"1952","journal-title":"Surgery"},{"key":"10.1016\/j.revmed.2025.11.002_bib0315","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S095925981500012X","article-title":"Subcutaneous fluid and drug delivery: safe, efficient and inexpensive","volume":"25","author":"Duems-Noriega","year":"2015","journal-title":"Rev Clin Gerontol"},{"key":"10.1016\/j.revmed.2025.11.002_bib0320","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.114.059238","article-title":"Subcutaneous absorption of biotherapeutics: knowns and unknowns","volume":"42","author":"Richter","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.revmed.2025.11.002_bib0325","first-page":"CD011386","article-title":"Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease","volume":"2015","author":"Ker","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2025.11.002_bib0330","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.revmed.2025.11.002_bib0335","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00006534-199004000-00010","article-title":"Age-related changes in skin blood flow at four anatomic sites of the body in males studied by xenon-133","volume":"85","author":"Tsuchida","year":"1990","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.revmed.2025.11.002_bib0340","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.revmed.2025.11.002_bib0345","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF01191807","article-title":"Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results","volume":"120","author":"Bertelli","year":"1994","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.revmed.2025.11.002_bib0350","doi-asserted-by":"crossref","first-page":"M169","DOI":"10.1093\/gerona\/52A.3.M169","article-title":"A systematic review of the evidence for hypodermoclysis to treat dehydration in older people","volume":"52","author":"Rochon","year":"1997","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.revmed.2025.11.002_bib0355","doi-asserted-by":"crossref","first-page":"e0237572","DOI":"10.1371\/journal.pone.0237572","article-title":"Subcutaneous hydration and medications infusions (effectiveness, safety, acceptability): a systematic review of systematic reviews","volume":"15","author":"Broadhurst","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2025.11.002_bib0360","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.archger.2003.09.003","article-title":"Hypodermoclysis (subcutaneous infusion) effective mode of treatment of dehydration in long-term care patients","volume":"38","author":"Arinzon","year":"2004","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.revmed.2025.11.002_bib0365","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.282.6266.823-d","article-title":"Subcutaneous infusions in the elderly","volume":"282","author":"Schen","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.revmed.2025.11.002_bib0370","article-title":"Severe phlebitis and cutaneous necrosis following peripheral administration of high-concentration potassium chloride: a case report and vascular access management implications","volume":"108","author":"Li","year":"2025","journal-title":"Sci Prog"},{"key":"10.1016\/j.revmed.2025.11.002_bib0375","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.285.6349.1167","article-title":"Administration of potassium by subcutaneous infusion in elderly patients","volume":"285","author":"Schein","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.revmed.2025.11.002_bib0380","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/J354v16n04_02","article-title":"Clinical pharmacokinetics of morphine","volume":"16","author":"Lugo","year":"2002","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0385","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt1974161part151","article-title":"Morphine metabolism in man","volume":"16","author":"Brunk","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.revmed.2025.11.002_bib0390","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0885-3924(00)00130-5","article-title":"A pharmacokinetic and tolerability evaluation of two continuous subcutaneous infusion systems compared to an oral controlled-release morphine","volume":"19","author":"Mikkelsen Lynch","year":"2000","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.revmed.2025.11.002_bib0395","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit\u00a0\u2013\u00a0MIDAZOLAM ACCORD 5mg\/mL, solution injectable\u00a0\u2013\u00a0base de donn\u00e9es publique des m\u00e9dicaments [Internet]. [cit\u00e9 5\u00a0juill 2025]. Disponible sur\u00a0: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=68529120&typedoc=R."},{"key":"10.1016\/j.revmed.2025.11.002_bib0400","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2125.2002.01665.x","article-title":"Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers","volume":"54","author":"Pecking","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2025.11.002_bib0405","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/026921639400800307","article-title":"Plasma concentrations of midazolam during continuous subcutaneous administration in palliative care","volume":"8","author":"Bleasel","year":"1994","journal-title":"Palliat Med"},{"key":"10.1016\/j.revmed.2025.11.002_bib0410","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12904-022-00934-3","article-title":"Evaluation of efficacy and safety of subcutaneous acetaminophen in geriatrics and palliative care (APAPSUBQ)","volume":"21","author":"El Khoury","year":"2022","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.revmed.2025.11.002_bib0415","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/0269216318772472","article-title":"Subcutaneous administration of paracetamol-good local tolerability in palliative care patients: an observational study","volume":"32","author":"Leheup","year":"2018","journal-title":"Palliat Med"},{"key":"10.1016\/j.revmed.2025.11.002_bib0420","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13063-019-3969-0","article-title":"Intravenous versus subcutaneous route pharmacokinetics of paracetamol (acetaminophen) in palliative care patients: study protocol for a randomized trial (ParaSCIVPallia)","volume":"21","author":"Vernant","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.revmed.2025.11.002_bib0425","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2021.14785","article-title":"Effect of prophylactic subcutaneous scopolamine butylbromide on death rattle in patients at the end of life: the SILENCE randomized clinical trial","volume":"326","author":"van\u00a0Esch","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2025.11.002_bib0430","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2515\/therapie\/2010066","article-title":"Administration des m\u00e9dicaments par voie sous-cutan\u00e9e en soins palliatifs","volume":"65","author":"Tanguy-Goarin","year":"2010","journal-title":"Therapie"},{"key":"10.1016\/j.revmed.2025.11.002_bib0435","unstructured":"Administration de m\u00e9dicaments par voie sous-cutan\u00e9e. [cit\u00e9 5\u00a0juill 2025]. Disponible sur\u00a0: https:\/\/www.hug.ch\/pharmacie\/recommandations\/document\/medic_voiesc [Internet]."},{"key":"10.1016\/j.revmed.2025.11.002_bib0440","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1191\/0269216304pm1006oa","article-title":"Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review","volume":"19","author":"Fonzo-Christe","year":"2005","journal-title":"Palliat Med"},{"key":"10.1016\/j.revmed.2025.11.002_bib0445","first-page":"CD006271","article-title":"Haloperidol for the treatment of nausea and vomiting in palliative care patients","volume":"2015","author":"Murray-Brown","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2025.11.002_bib0450","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jamda.2020.04.035","article-title":"Subcutaneous antibiotic therapy: the why, how, which drugs and when","volume":"22","author":"Hern\u00e1ndez-Ruiz","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.revmed.2025.11.002_bib0455","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1185\/03007990903432900","article-title":"Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers","volume":"26","author":"Harb","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.revmed.2025.11.002_bib0460","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf313","article-title":"Pharmacokinetics of subcutaneous and intravenous ceftriaxone in an older population: the PhASAge study","volume":"12","author":"Roubaud-Baudron","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.revmed.2025.11.002_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkac383","article-title":"Subcutaneously administered antibiotics: a review","volume":"78","author":"Jumpertz","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0470","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.medmal.2014.03.007","article-title":"Subcutaneous and intravenous ceftriaxone administration in patients more than 75\u00a0years of age","volume":"44","author":"Gauthier","year":"2014","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.revmed.2025.11.002_bib0475","unstructured":"Information de s\u00e9curit\u00e9\u00a0\u2013\u00a0ceftriaxone (Roc\u00e9phine\u00ae et g\u00e9n\u00e9riques [Internet]). ANSM. [cit\u00e9 24\u00a0oct 2025]. Disponible sur\u00a0: https:\/\/ansm.sante.fr\/informations-de-securite\/ceftriaxone-rocephine-r-et-generiques-rappel-sur-les-voies-dadministration."},{"key":"10.1016\/j.revmed.2025.11.002_bib0480","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/jac\/dkad115","article-title":"Evaluation of the tolerance of ceftriaxone by subcutaneous route in patients\u226575\u00a0years old in geriatric departments: a prospective observational study","volume":"78","author":"Renoncourt","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0485","unstructured":"Antibioth\u00e9rapie sous-cutan\u00e9e. Recommandations de bonne pratique clinique. SPILF\/SFGG 2025. [cit\u00e9 24\u00a0oct 2025]. Disponible sur\u00a0: https:\/\/www.infectiologie.com\/UserFiles\/File\/jni\/2025\/com\/intervention-sg02-03.pdf [Internet]."},{"key":"10.1016\/j.revmed.2025.11.002_bib0490","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1517\/14656566.9.1.23","article-title":"A potent class of antibiotics","volume":"9","author":"Nicolau","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0495","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkx477","article-title":"Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection","volume":"73","author":"Goutelle","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0500","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/AAC.00836-09","article-title":"Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients","volume":"54","author":"Frasca","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0505","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1093\/jac\/dkz385","article-title":"Is the subcutaneous route an alternative for administering ertapenem to older patients? PHACINERTA study","volume":"74","author":"Roubaud Baudron","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0510","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1007\/s00134-003-1859-z","article-title":"Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors","volume":"29","author":"Barbot","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.revmed.2025.11.002_bib0515","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s12879-016-1955-7","article-title":"Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration","volume":"16","author":"Peeters","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.revmed.2025.11.002_bib0520","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1093\/jac\/dkx242","article-title":"Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen","volume":"72","author":"Cazaubon","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0525","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jamda.2019.08.010","article-title":"Safety of subcutaneous piperacillin\/tazobactam administration compared to intravenous administration: Propensity score-matched cohort study","volume":"21","author":"Kobayashi","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.revmed.2025.11.002_bib0530","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jac\/dkae397","article-title":"Safety, tolerability and pharmacokinetics of subcutaneous cefazolin as an alternative to intravenous administration","volume":"80","author":"Murray","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0535","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.medmal.2019.12.006","article-title":"Clinical evaluation of subcutaneous administration of cefepime","volume":"50","author":"Pilmis","year":"2020","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.revmed.2025.11.002_bib0540","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/ehjcvp\/pvae083","article-title":"Subcutaneous furosemide in heart failure: a systematic review","volume":"11","author":"Osmanska","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.revmed.2025.11.002_bib0545","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.cardfail.2016.06.041","article-title":"Pharmacokinetic and pharmacodynamic response after subcutaneous administration of a novel furosemide formulation","volume":"22","author":"Sica","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.revmed.2025.11.002_bib0550","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1089\/jpm.2020.0414","article-title":"Subcutaneous levetiracetam for the management of seizures at the end of life: an audit and updated literature review","volume":"24","author":"Sutherland","year":"2021","journal-title":"J Palliat Med"},{"key":"10.1016\/j.revmed.2025.11.002_bib0555","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/bmjspcare-2016-001261","article-title":"Subcutaneous levetiracetam for the management of seizures at the end of life","volume":"8","author":"Sutherland","year":"2018","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.revmed.2025.11.002_bib0560","first-page":"125","article-title":"Administration of levetiracetam via subcutaneous infusion for seizure control in the palliative care setting: a narrative review","volume":"12","author":"Beschi","year":"2024","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.revmed.2025.11.002_bib0565","unstructured":"Vaccine administration route and site\u00a0|\u00a0CDC [Internet]. 2025 [cit\u00e9 10\u00a0juill 2025]. Disponible sur\u00a0: https:\/\/www.cdc.gov\/vaccines\/hcp\/admin\/administer-vaccines.html."},{"key":"10.1016\/j.revmed.2025.11.002_bib0570","doi-asserted-by":"crossref","first-page":"972468","DOI":"10.3389\/fphar.2022.972468","article-title":"Inherited and acquired vitamin B12\u00a0deficiencies: which administration route to choose for supplementation?","volume":"13","author":"Elangovan","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.revmed.2025.11.002_bib0575","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/emj.19.3.249","article-title":"Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Intravenous or intramuscular\/subcutaneous naloxone in opioid overdose","volume":"19","author":"Clarke","year":"2002","journal-title":"Emerg Med J"},{"key":"10.1016\/j.revmed.2025.11.002_bib0580","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/bja\/64.1.53","article-title":"Additional subcutaneous administration of flumazenil does not shorten recovery time after midazolam","volume":"64","author":"Luger","year":"1990","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.revmed.2025.11.002_bib0585","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1159\/000527655","article-title":"The choice between intravenous and subcutaneous immunoglobulins: aspects for consideration","volume":"107","author":"von\u00a0Achenbach","year":"2022","journal-title":"Pharmacology"},{"key":"10.1016\/j.revmed.2025.11.002_bib0590","unstructured":"Pr\u00e9vention des infections li\u00e9es aux cath\u00e9ters p\u00e9riph\u00e9riques vasculaires et sous-cutan\u00e9s\u00a0\u2013\u00a0mai 2019 [Internet]. [cit\u00e9 24\u00a0oct 2025]. Disponible sur\u00a0: https:\/\/www.sf2h.net\/publications\/prevention-des-infections-liees-aux-catheters-peripheriques-vasculaires-et-sous-cutanes-mai-2019.html."},{"key":"10.1016\/j.revmed.2025.11.002_bib0595","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1001\/jama.1983.03340130024016","article-title":"Hypodermoclysis","volume":"250","author":"Schen","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2025.11.002_bib0300","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1532-5415.1984.tb02002.x","article-title":"Nutrition by hypodermoclysis","volume":"32","author":"Berger","year":"1984","journal-title":"J Am Geriatr Soc"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325012809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325012809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:41:02Z","timestamp":1771429262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866325012809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0248866325012809"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2025.11.002","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perfusion sous-cutan\u00e9e\u00a0: indications, modalit\u00e9s et tol\u00e9rance","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2025.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}